See more : Supermax Corporation Berhad (SPMXF) Income Statement Analysis – Financial Results
Complete financial analysis of Titan Medical Inc. (TMDI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Titan Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Yunnan Chihong Zinc & Germanium Co., Ltd. (600497.SS) Income Statement Analysis – Financial Results
- UPAY, Inc. (UPYY) Income Statement Analysis – Financial Results
- Goldenbridge Acquisition Limited (GBRGR) Income Statement Analysis – Financial Results
- Lytone Enterprise, Inc. (1293.TWO) Income Statement Analysis – Financial Results
- Nektar Therapeutics (0UNL.L) Income Statement Analysis – Financial Results
Titan Medical Inc. (TMDI)
About Titan Medical Inc.
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.09M | 20.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 58.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 20.09M | 20.00M | -58.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.96M | 7.94M | 51.42M | 32.86M | 12.90M | 22.58M | 38.21M | 10.68M | 5.35M | 4.64M | 12.48M | 1.57M | 158.77K | 1.44M | 150.91K |
| General & Administrative | 12.43M | 7.49M | 7.81M | 6.80M | 5.97M | 4.93M | 3.53M | 3.50M | 3.48M | 3.08M | 3.07M | 1.97M | 548.18K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 140.98K | -5.00 | 2.00 | 1.00 | -5.00 | 1.00 | -4.00 | -114.22K | 9.82K | 240.83K | 134.87K | 11.76K | 0.00 | 0.00 |
| SG&A | 12.43M | 7.63M | 7.81M | 6.80M | 5.97M | 4.93M | 3.53M | 3.50M | 3.37M | 3.09M | 3.31M | 2.11M | 559.94K | 692.32K | 132.00K |
| Other Expenses | 699.00K | 0.00 | 32.55K | 29.04K | 17.36K | 24.64K | 32.39K | 23.66K | 118.75K | 155.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 51.08M | 15.57M | 59.27M | 39.69M | 18.88M | 27.53M | 41.77M | 14.20M | 8.83M | 7.88M | 15.79M | 3.68M | 718.71K | 2.13M | 282.91K |
| Cost & Expenses | 51.08M | 15.80M | 59.73M | 38.71M | 19.43M | 27.81M | 42.64M | 14.77M | 9.13M | 7.85M | 15.89M | 3.72M | 741.82K | 2.15M | 303.09K |
| Interest Income | 73.00K | 29.14K | 115.58K | 288.30K | 17.44K | 7.54K | 88.64K | 305.29K | 59.16K | 87.26K | 93.11K | 33.80K | 28.16K | 16.69K | 0.00 |
| Interest Expense | 125.00K | 1.09M | 422.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 165.48K | 27.57K |
| Depreciation & Amortization | 699.00K | 236.84K | 32.56K | 29.04K | 17.36K | 24.64K | 32.39K | 23.66K | 289.47K | 132.65K | 95.68K | 41.41K | 23.11K | 19.19K | 20.19K |
| EBITDA | -13.98M | -22.86M | -41.45M | -22.61M | -33.57M | -23.30M | -41.38M | -13.43M | -8.78M | -7.63M | -15.70M | -3.65M | -690.55K | -2.12M | -282.91K |
| EBITDA Ratio | -69.57% | -114.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.68M | -23.09M | -41.48M | -22.64M | -33.59M | -23.32M | -41.41M | -13.45M | -9.07M | -7.76M | -15.80M | -3.69M | -713.66K | -2.14M | -303.09K |
| Operating Income Ratio | -73.05% | -115.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 16.19M | -1.09M | 10.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -14.80M | -24.18M | -41.91M | -22.64M | -33.59M | -23.32M | -41.41M | -13.45M | -9.07M | -7.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -73.67% | -120.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 56.00K | 1.09M | 422.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 165.48K | 27.57K |
| Net Income | -14.86M | -25.28M | -42.33M | -22.64M | -33.59M | -23.32M | -41.41M | -13.45M | -9.07M | -7.76M | -15.80M | -3.69M | -713.66K | -2.30M | -330.66K |
| Net Income Ratio | -73.95% | -126.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.22 | -0.38 | -1.38 | -1.36 | -4.25 | -4.77 | -11.92 | -4.29 | -3.87 | -3.63 | -8.73 | -2.58 | -0.64 | -2.94 | -8.50 |
| EPS Diluted | -0.22 | -0.38 | -1.38 | -1.36 | -4.25 | -4.77 | -11.92 | -4.29 | -3.87 | -3.63 | -8.73 | -2.58 | -0.64 | -2.94 | -8.50 |
| Weighted Avg Shares Out | 67.01M | 67.01M | 30.69M | 16.64M | 7.90M | 4.89M | 3.48M | 3.14M | 2.34M | 2.14M | 1.81M | 1.43M | 1.11M | 782.20K | 38.89K |
| Weighted Avg Shares Out (Dil) | 67.01M | 67.01M | 30.69M | 16.64M | 7.90M | 4.89M | 3.48M | 3.14M | 2.34M | 2.14M | 1.81M | 1.43M | 1.11M | 782.20K | 38.89K |
3 Common Myths About Penny Stocks Debunked
Debunking common myths about trading penny stocks in 2023 The post 3 Common Myths About Penny Stocks Debunked appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Titan Medical Inc. (TMDI) Q3 2022 Earnings Call Transcript
Titan Medical Inc. (NASDAQ:TMDI ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Kristen Galfetti - VP of IR Cary Vance - President & CEO Stephen Lemieux - CFO Conference Call Participants Operator Good morning,...
Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022
Webcast to Follow Announcement Webcast to Follow Announcement
Titan Medical to Present at the H.C. Wainwright Global Investment Conference
TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos™ robotic single access...
Titan Medical Inc. (TMDI) CEO Cary Vance on Q2 2022 Results - Earnings Call Transcript
Titan Medical Inc. (NASDAQ:TMDI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kristen Galfetti - Vice President of Investor Relations Cary Vance - President & Chief Executive Officer Stephen Lemieux - Chief Financial Officer...
Titan Medical to Issue Second Quarter 2022 Financial Results on August 11, 2022
Webcast to Follow Announcement Webcast to Follow Announcement
Titan Medical Inc. (TMDI) CEO Paul Cataford on Q1 2022 Results - Earnings Call Transcript
Titan Medical Inc. (NASDAQ:TMDI ) Q1 2022 Results Conference Call May 12, 2022 8:30 AM ET Company Participants Kristen Galfetti - Vice President of Investor Relations Paul Cataford - Interim President & CEO Stephen Lemieux - Chief Financial Officer Conference...
Titan Medical to Issue First Quarter 2022 Financial Results on May 12, 2022
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its first quarter 2022 financial results prior to market opening on Thursday, May...
Titan Medical Inc. (TMDI) CEO Paul Cataford on Q4 2021 Results - Earnings Call Transcript
Titan Medical Inc. (TMDI) CEO Paul Cataford on Q4 2021 Results - Earnings Call Transcript
Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2021
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and twelve months ended December...
Source: https://incomestatements.info
Category: Stock Reports